UPDATE: Paradigm Capital Reiterates Buy Rating, Lowers PT on IMRIS on Additions to Balance Sheet

In a report published Wednesday, Paradigm Capital analyst Alan Ridgeway reiterated his Buy rating on IMRIS IMRS, but slightly lowered his price target from $6.00 to $5.50. In the report, Ridgeway noted, “IM is a world leader in integrated image guided therapy solutions that allow for safe, high-resolution images to be obtained for patients during surgical or radiation therapy procedures. IM's systems are now installed in >30 hospitals around the world and sales of the company's initial products appear to be accelerating following a slowdown in 2011. Solidified by solid management, we believe IM provides investors with market-leading exposure to the large and growing intra-procedure imaging market.” IMRIS closed on Tuesday at $3.58.